Cencora, Inc. (NYSE:COR) Shares Bought by CWA Asset Management Group LLC

CWA Asset Management Group LLC increased its stake in Cencora, Inc. (NYSE:COR) by 23.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,562 shares of the company’s stock after acquiring an additional 298 shares during the quarter. CWA Asset Management Group LLC’s holdings in Cencora were worth $351,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Concord Wealth Partners acquired a new position in shares of Cencora in the 3rd quarter valued at $30,000. SYSTM Wealth Solutions LLC purchased a new stake in Cencora during the second quarter valued at about $36,000. Ashton Thomas Securities LLC acquired a new position in shares of Cencora in the third quarter worth about $41,000. Fairscale Capital LLC purchased a new position in shares of Cencora in the second quarter worth approximately $54,000. Finally, Modus Advisors LLC purchased a new position in shares of Cencora in the fourth quarter worth approximately $54,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 94,696 shares of company stock valued at $22,862,734 over the last 90 days. 15.80% of the stock is owned by company insiders.

Cencora Stock Performance

NYSE:COR opened at $237.63 on Thursday. The firm has a market capitalization of $45.93 billion, a PE ratio of 31.64, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 1 year low of $209.32 and a 1 year high of $253.27. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The firm’s fifty day simple moving average is $237.38 and its 200 day simple moving average is $233.51.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.93%. This is a boost from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on COR. Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partners decreased their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Evercore ISI raised their price objective on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $275.60.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.